Skip to content

A multicenter randomized controlled study on the protective effect of early preventive use of caffeine citrate on the brain of premature infants

A multicenter randomized controlled study on the protective effect of early preventive use of caffeine citrate on the brain of premature infants

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057419
Enrollment
Unknown
Registered
2022-03-11
Start date
2022-04-01
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

apnea of prematurity

Interventions

test group:Caffeine use within 6 hours after birth
control group:The original clinical treatment plan remains unchanged (or 12 hours after birth) using caffeine

Sponsors

Pediatric Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: 1.27 weeks < gestational age < 32 weeks

Exclusion criteria

Exclusion criteria: 1. Died within 24 hours of admission or gave up treatment within 24 hours after taking medication; 2. Severe liver and kidney insufficiency, cardiac insufficiency; 3. Preterm infants with severe congenital malformations or congenital developmental abnormalities, congenital metabolic disorders, and chromosomal abnormalities; 4. Severe apnea or bradycardia 10 minutes before birth requires emergency tracheal intubation; 5. Children whose family members refuse or the attending doctor on duty thinks they are not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Incidence of endpoint outcome events (death or IVH or cystic or diffuse PVL);

Secondary

MeasureTime frame
Incidence of apnea within 72 hours of medication;Length of hospital stay, duration of respiratory support, and duration of oxygen use;Changes in cerebral cortical activity and cerebral blood oxygen during drug injection;death during hospitalization;Ultrasound-confirmed III-IV intracranial hemorrhage;Qualitative scoring of white matter and gray matter abnormalities by brain magnetic resonance imaging in stable stage;12-18 months neurodevelopmental outcomes (GMs score), cerebral palsy (GMFCS score), cognitive impairment (MDI score);Neonatal Necrotizing Enterocolitis (NEC)/Bronchopulmonary Dysplasia (BPD)/Retinopathy of Prematurity (ROP) / Incidence of Patent Ductus Arteriosus (PDA);Drug Safety Indicators;

Countries

China

Contacts

Public ContactLaishuan Wang

Pediatric Hospital Affiliated to Fudan University

laishuanwang@fudan.edu.cn+86 13611843863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026